Kalydeco (ivacaftor) to be funded for under 6's, by NHS England

The treatment is eligible for 9 different rare genotypes and currently funded for ages 2-5, on the NHS in Scotland. At the moment it is only funded in England For those over six years old. Kalydeco has been proven to treat the underlying cause of cystic fibrosis in those 9 gene mutations, to significantly increase lung function, slow the progression of cystic fibrosis and halve hospital admissions.

Please help William and other children effected by cystic fibrosis by signing this petition